Amfexa® (dexamfetamine sulfate)
Amfexa® can be used as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years when response to previous methylphenidate treatment is considered clinically inadequate. 1 Amfexa tablets are not licensed for use in adults for ADHD
Dosing & administration
- At the start of treatment with Amfexa®, dose titration is necessary 1
- Recommended starting daily dose is 5 mg once or twice daily e.g. at mealtimes 1
- Dose can be increased if necessary by weekly increments of 5 mg daily, depending on how well it’s tolerated and working. The maximum daily dose in children and adolescents usually is 20 mg, although doses of 40 mg may in rare cases be necessary for optimum titration1
- When treating ADHD, it helps to carefully choose the time treatment is taken so it combats any school or behavioural difficulties most effectively 1
Safety and Monitoring
For full safety and monitoring information please refer to section 4 of the SmPC or click here.
References
Medikinet® XL
Medikinet® XL
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.
Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at the Yellow Card Scheme; https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should be reported to MEDICE UK at medicalinformation@medice.co.uk
Please retain the reported medication and packaging for further investigation by MEDICE UK.
Reporting side effects can provide more information on the safety of this medicine.
Adverse events should be reported. Reporting forms and information can be found at the Yellow Card Scheme; https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should be reported to MEDICE UK at medicalinformation@medice.co.uk
Please retain the reported medication and packaging for further investigation by MEDICE UK.
Reporting side effects can provide more information on the safety of this medicine.